

Original Research Article

## Studies on Haematological Parameters of Patients with Pulmonary Tuberculosis before Treatment with Different Ranges of CD4 Levels in Southeast, Nigeria

Obeagu Emmanuel Ifeanyi<sup>1, 2\*</sup> and Okorie Hope M<sup>2</sup>

<sup>1</sup>Medical Laboratory Science, University Health Services, Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria

<sup>2</sup>Department of Medical Laboratory Science, Imo State University, Owerri, Nigeria

**\*Corresponding Author**

Obeagu Emmanuel Ifeanyi

**Article History**

Received: 11.11.2019

Accepted: 18.11.2019

Published: 30.11.2019

**Abstract:** Pulmonary tuberculosis is increasing at alarming rate with high level of resistance to chemotherapy. The study was done to determine the changes in haematological parameters in relation to ranges of CD4 of patients with pulmonary tuberculosis before treatment in Southeast, Nigeria. A total of one hundred subjects were recruited for the study comprising 50 subjects each for Patients with pulmonary tuberculosis before treatment with CD4 count of 100-200 cell/L and 201-300 cells/L drawn from the Health institution. The study was done in a tertiary health institution in Southeast, Nigeria. Three milliliters (3ml) of venous blood was collected from each subject and was dispensed into bottles containing di-potassium salt of ethylenediamine tetra-acetic acid (K<sub>2</sub>-EDTA) at a concentration of 1.5mg/ml of blood and was used for full blood count and CD4 count. Haematological parameters were analysed using Mindray BC-5300. The results were expressed as mean± standard deviation. The data were analysed with the statistical package for social science (SPSS) version 21 using t-test, ANOVA and the level of significance was set at P<0.05. The results showed decrease in neutrophil (61.85±1.94%, 63.94±2.99%, P= 0.046) and MCV (78.09±1.64fl, 79.50±1.02fl, P=0.015) and no significant difference in WBC (5.53±0.36 X10<sup>9</sup>/L, 5.32±0.58 X10<sup>9</sup>/L, P=0.285), lymphocytes (23.08±2.21%, 21.16±3.16%, P=0.087), monocytes (11.37±0.81%, 11.49±1.06, P=0.766), eosinophils (2.28±0.61%, 2.16±0.33, P=0.574), basophils (1.42±0.26%, 1.23±0.24%, P=0.126), RBC (3.64±0.20 X10<sup>12</sup>/L, 3.63±0.18 X10<sup>12</sup>/L, P=0.839), haemoglobin (10.93±0.60g/dl, 10.89±0.55g/dl), PCV (32.80±1.80%, 32.66±1.64%, P=0.840), MCH (27.47±0.49pg, 27.55±0.32pg, P=0.646), MCHC (35.14±0.45g/dl, 35.31±0.36, P=0.306), Platelet (140.81±3.28 X10<sup>9</sup>/L, 141.12±4.05 X10<sup>9</sup>/L, P=0.833) and ESR (47.66±2.36mm/hr, 47.46±2.98mm/hr) of the of TB patients based on ranges of CD4 counts. The study shows that the range of CD4 count has no much changes in haematological parameters except decrease in neutrophil and MCV.

**Keywords:** Pulmonary Tuberculosis patients, CD4, Haematological parameters.

### INTRODUCTION

It has been shown that pulmonary tuberculosis (TB) is a long term bacterial disease linked to *Mycobacterium tuberculosis* (MTB) complex which mostly affects the lungs; (pulmonary TB (PTB), but can affect other sites as well; (extra-pulmonary TB (EPTB) as reported by Thumamo *et al.*, [1]. *Mycobacterium tuberculosis*, the causative organism for human pulmonary tuberculosis disease, is an old enemy. Historically; pulmonary tuberculosis (PTB) has a lineage that could be traced to the earliest history of mankind having been in existence since 150,000-200,000 years ago [2]. It is reported that pulmonary tuberculosis first made its ravaging presence felt in Europe and later got to the US, Africa and Asia through voyagers and early settlers [2]. *Mycobacterium tuberculosis* is an acid fast facultative intracellular rod shaped bacterium. It is non- motile, obligate aerobe with stretched generation time and prefers especially to localize in macrophages [3, 4].

It is believed that pulmonary tuberculosis (PTB) is a global public health problem and is the second leading cause of death. All inclusive, the disease takes a life every 20 seconds [5, 6]. In Nigeria, pulmonary tuberculosis is a major public health problem with an estimated prevalence of 616 cases per 100,000. Nigeria leads in Africa, and fourth among the 22 high pulmonary TB burden countries in the world, and no fewer than 460,000 cases of pulmonary TB are reported annually in Nigeria [7]. Ita and Udofia [8]

**Copyright @ 2019:** This is an open-access article distributed under the terms of the Creative Commons Attribution license which permits unrestricted use, distribution, and reproduction in any medium for non commercial use (NonCommercial, or CC-BY-NC) provided the original author and source are credited.

opined the prevalence rate of 38.5% pulmonary TB in Ikot Ekpene and 17.6% in Itu Local Government area of Akwa Ibom State; they reported that male subjects had a higher incidence rate of pulmonary TB (35.6%) compared to 29.6% in female. Similarly, Nwanta *et al.*, [9] reported an overall prevalence rate of 37.9% pulmonary TB in Enugu state, Nigeria. Some reports have shown that haematological parameters are good indicators of health status [10-12].

The study was done to determine the changes in haematological parameters in relation to CD 4 ranges in patients with pulmonary tuberculosis before treatment in Southeast, Nigeria.

## **MATERIAL AND METHODS**

### **STUDY AREA**

This study was carried out at the directly observed treatment-short course Tuberculosis (TB DOTS) centre of Federal Medical Centre, Umuahia.

### **SUBJECTS**

A total of one hundred subjects were recruited for the study comprising 50 subjects each for Patients with pulmonary tuberculosis before treatment with CD4 count of 100-200 cell/L and 201-300 cells/L drawn from the Health institution.

### **SAMPLE COLLECTION**

Three milliliters (3ml) of venous blood was collected from each subject and was dispensed into bottles containing dipotassium salt of ethylenediamine tetra-acetic acid (K<sub>2</sub>-EDTA) at a concentration of 1.5mg/ml of blood and was used for full blood count and CD4 count.

### **LABORATORY PROCEDURES**

All reagents were commercially purchased and the manufacturer's standard operating procedures were strictly adhered to.

### **DETERMINATIONS**

A. Ziehl-Nelson Technique for *Mycobacterium tuberculosis* diagnosis [13].

#### **Procedure**

##### **Smear Preparation**

A piece of clean stick was used to transfer and spread sputum materials evenly covering an area of about 15-20mm diameter on a glass slide. The smear was air dried and labeled.

##### **Heat Fixation**

The slide with the smear uppermost was rapidly passed three times through the flame of a Bunsen burner and was allowed to cool.

##### **Ziehl-Nelson Staining**

The slide containing the smear was placed on a slide rack and the smear covered with carbol fuchsin stain. The stain was heated until vapour just begins to rise. The heated stain was allowed to remain on the slide for 5 minutes. The stain was washed off with clean water and then covered with 3% v/v acid alcohol for 5 minutes or until smear is sufficiently decolourised, that is pale pink. The slide was washed off with clean water. The smear was covered with Methylene blue stain for 2 minutes and then washed off with clean water. The back of the slide was wiped clean and placed in a draining rack for the smear to air dry.

##### **Mycobacterium Tuberculosis Diagnosis**

The smear was examined microscopically using the X100 oil immersion objective. Scanning of the smear was done systematically and when any definite red bacillus is seen, it was reported as AFB positive.

##### **GeneXpert method for detection of *Mycobacterium tuberculosis* and Rifampicin resistance (GeneXpert MTB/FIF)**

##### **Procedure**

The assay consists of a single-use multi-chambered plastic cartridge pre-loaded with the liquid buffers and lyophilised reagent beads necessary for sample processing.

##### **DNA extraction and hemi-nested real-time PCR**

Sputum samples were treated with the sample reagent (containing NaOH and isopropanol). The sample reagent was added in the ratio of 2:1 to the sputum sample and the closed specimen container was manually agitated twice during 15 minutes of incubation at room temperature. 2ml of the treated sample was transferred into the cartridge, the cartridge was loaded into the GeneXpert instrument and automatic step completed the remaining assay steps.

The assay cartridge also contained lyophilized *Bacillus globigii* spores which served as an internal sample processing step and the resulting *B.globigii* DNA was amplified during PCR step. The standard user interface indicates the presence or absence of *Mycobacterium tuberculosis*, the presence or absence of rifampicin resistance and semi quantitative estimate of *Mycobacterium tuberculosis* concentration (high, medium, low and very low). Assays that are negative for *Mycobacterium tuberculosis* and also negative for *B.globigii* internal control was reported as invalid.

**Determination of CD4 count by flowcytometry (Partec Cyflow counter), Germany**

**Procedure**

All required reagents was brought to room temperature and 850µl of the count check bead green will be analysed to ensure that the cyflow machine is working properly. The desired numbers of rohren test tubes was placed in a test tube rack. 20µl of CD4 easy count kits (CD4 Mab-PE) were pipetted into different test tubes labeled appropriately for the assay. Then, 20µl of blood sample was also pipette into each respective test tube and incubated in the dark for 15 minutes at room temperature after mixing properly. This was followed by the addition of 850 µl easy count. No lyse buffer was added to each test tube. This was mixed properly to avoid air bubbles and analysed on the Partec Cyflow. The result was displayed and copied from the screen.

**Full blood count by automation using Mindray BC-5300, China**

**Procedure**

The sample is EDTA bottle was placed in the spiral mixer and allowed to mix very well. Whole blood mode was activated in the LCD screen, the sample no (code) was inputted via key board and then the key will be selected. Then the sample was mixed very well again and the cap was removed and inserted into the probe and the SART button was pressed. When the LCD screen displays ANALYSING; the sample was removed and recapped. The analyser was executed automatic analysis and displays the result on LCD screen.

**Ethical Consideration**

The details of the research were explained to the subjects and written consents obtained from them and were assured of joining the study willingly and confidentiality also assured. The subjects who gave their consents were allowed to participate in the study.

**STATISTICAL ANALYSIS**

The results were expressed as mean± standard deviation. The data were analysed with the statistical package for social science (SPSS) version 21 using t-test, ANOVA and the level of significance was set at P<0.05.

**Table-1: Mean ±SD Values of Haematological Parameters of Patients with Pubmonary TB Based on the Range of CD4 Count**

Parameters	100-200 cell/L	201-300 cells/L	P-VALUE
WBC (X10 <sup>9</sup> /L)	5.53±0.36	5.32±0.58	0.285 <sup>NS</sup>
NEUTROPHIL (%)	61.85±1.94	63.94±2.99	0.046*
LYMPHOCYTES (%)	23.08±2.21	21.16±3.16	0.087 <sup>NS</sup>
MONOCYTES (%)	11.37±0.81	11.49±1.06	0.766 <sup>NS</sup>
EOSINOPHILS (%)	2.28±0.61	2.16±0.33	0.574 <sup>NS</sup>
BASOPHILS (%)	1.42±0.26	1.23±0.24	0.126 <sup>NS</sup>
RBC(X10 <sup>12</sup> /L)	3.64±0.20	3.63±0.18	0.839 <sup>NS</sup>
HAEMOGLOBIN (g/dl)	10.93±0.60	10.89±0.55	0.840 <sup>NS</sup>
PCV (%)	32.80±1.80	32.66±1.64	0.840 <sup>NS</sup>
MCV(fl)	78.09±1.64	79.50±1.02	0.015*
MCH(pg)	27.47±0.49	27.55±0.32	0.646 <sup>NS</sup>
MCHC(g/dl)	35.14±0.45	35.31±0.36	0.306 <sup>NS</sup>
PLT(X10 <sup>9</sup> /L)	140.81±3.28	141.12±4.05	0.833 <sup>NS</sup>
ESR(mm/hr)	47.66±2.36	47.46±2.98	0.848 <sup>NS</sup>

The results showed decrease in neutrophil (61.85±1.94%, 63.94±2.99%, P= 0.046) and MCV (78.09±1.64fl, 79.50±1.02fl, P=0.015) and no significant difference in WBC (5.53±0.36 X10<sup>9</sup>/L, 5.32±0.58 X10<sup>9</sup>/L, P=0.285), lymphocytes (23.08±2.21%,21.16±3.16%, P=0.087), monocytes (11.37±0.81%,11.49±1.06, P=0.766), eosinophils (2.28±0.61%, 2.16±0.33, P=0.574), basophils (1.42±0.26%, 1.23±0.24%, P=0.126), RBC(3.64±0.20 X10<sup>12</sup>/L, 3.63±0.18 X10<sup>12</sup>/L, P=0.839), haemoglobin (10.93±0.60g/dl, 10.89±0.55g/dl), PCV (32.80±1.80%,32.66±1.64%, P=0.840), MCH (27.47±0.49pg, 27.55±0.32pg, P=0.646), MCHC (35.14±0.45g/dl, 35.31±0.36, P=0.306), Platelet (140.81±3.28 X10<sup>9</sup>/L, 141.12±4.05 X10<sup>9</sup>/L, P=0.833) and ESR (47.66±2.36mm/hr, 47.46±2.98mm/hr) of the of TB patients based on ranges of CD4 counts.

## DISCUSSION

Pulmonary tuberculosis is a major infectious disease with very high incidence in developing countries like Nigeria which continues to rise [14, 15]. The study revealed decrease in neutrophils and MCV of the patients with pulmonary tuberculosis with CD4 count of 100-200 cells/L compared to pulmonary TB patients with CD4 count of 201-300 cells/L. The presence of bacterial pathogens in patients' blood stream often stimulates the production of plasma cytokines and other immunomodulatory proteins [16]. Other haematological parameters when compared among the two groups of TB patients with different range of CD4 count showed no significant difference. CD4 count has been utilized as a measure of immune status and pulmonary tuberculosis is known to suppress immune status leading to high mortality rates if not promptly and well treated with appropriate anti-tuberculosis drugs. The decrease in neutrophils in TB patients with CD4 of 100-200 cells/L may be due to bone marrow suppression and will affect the response to opportunistic infections. This will also affect cytokine release and other immune response. The study also showed decrease in MCV which could be linked to anaemia. In patients with pulmonary TB, anaemia is strongly associated with morbidity and risk of death [17-19].

## CONCLUSION

The study shows that the range of CD4 count has no much changes in haematological parameters except decrease in neutrophil and MCV. The changes in neutrophils and MCV should be monitored in patients with pulmonary tuberculosis in relation to CD4 level to ensure stable immunity in the patients.

## REFERENCES

1. Thumamo, B. P., Asuquo, A. E., Abia-Bassey, L. N., Lawson, L., Hill, V., Zozio, T., ... & Rastogi, N. (2012). Molecular epidemiology and genetic diversity of Mycobacterium tuberculosis complex in the Cross River State, Nigeria. *Infection, Genetics and Evolution*, 12(4), 671-677.
2. Okonkwo, R. C., Anyabolu, A. E., Ifeanyichukwu, M., Kalu, S. O., Onwunzo, M. C., & Chukwuka, C. (2013). Prevalence of HIV Infection in Pulmonary Tuberculosis Suspects; Assessing the Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria. *Advances in Life Science and Technology*, 14(1):87-90
3. Zumla, A., Raviglione, M., Hafner, R., & von Reyn, C. F. (2013). Tuberculosis. *New England Journal of Medicine*, 368:745-755.
4. Gupta-Wright, A., & Lawn, S. D. (2015). HIV-associated Tuberculosis. *European Medical Journal*, 60(5): 60-70.
5. Divangahi, M. (2013). The New Paradigm of Immunity to Tuberculosis. *Nature*, 4:294
6. Yang, C., Shen, X., Peng, Y., Lan, R., Zhao, Y., Long, B., ... & Gui, X. (2015). Transmission of Mycobacterium tuberculosis in China: a population-based molecular epidemiologic study. *Clinical Infectious Diseases*, 61(2), 219-227.
7. WHO Report. (2008). Global Tuberculosis Control: Surveillance, Planning & Financing.
8. Itah, A. Y., & Udofia, S. M. (2005). Epidemiology and Endemicity of Pulmonary Tuberculosis (PTB) in Southeastern Nigeria. *Southeast Asian Journal of Tropical Medicine & Public Health*, 36(2), 317-323.
9. Nwanta, J. A., Umeononigwe, C. N., Abonyi, G. E., & Onunkwo, J. I. (2011). Retrospective study of bovine and human tuberculosis in abattoirs and hospitals in Enugu State, Southeast Nigeria. *Journal of Public Health and Epidemiology*, 3: 329-336.
10. Obeagu, E. I., Obeagu, G. U., Chijioke, U. O., Ofor, I. B., & Amilo, G. I. (2017). Analysis of Alterations in Selected Haematological Parameters of Ascariasis Patients in Umudike, Abia State, Nigeria. *Ann Clin Lab Res*, 5(3), 193.
11. Obeagu, E. I., Azuonwu, O., Didia, B. C., & Obeagu, G. U. (2018). Determination of Haematological Changes Associated with Syphilis in Subjects in Umudike, Abia State, Nigeria. *Cohesive Journal of Microbiology and Infectious Disease*, 1(1): 505.
12. Obeagu, E. I., Obeagu, G. U., & Anaebo, Q. B. N. (2019). Studies on Serum Erythropoietin and Red Cell Indices of Patients with Urinary Tract Infection in Southeast, Nigeria. *Saudi Journal of Biomedical Research*, 4(10): 333-337.
13. Cheesbrough, M. (2006). District Laboratory Practice in Tropical Countries Part 2 (2<sup>nd</sup>ed.). Cambridge University Press. 253-266.
14. Akpan, P. A., Akpotuzor, J. O., & Akwiwu, E. C. (2012). Some Haematological Parameters of Tuberculosis (TB) Infected Africans: The Nigerian Perspective. *Journal of Natural Sciences Research*, 2(1):50-56.
15. Obeagu E. I., Okoroibu I. L., Nwanjo H. U., & Nwosu D. C. (2019). Evaluation of haematological parameters of tuberculosis patients in umuahia. *European Journal of Pharmaceutical and Medical Research*, 6(7): 693-699.
16. Koyama, S., Ishii, K. J., Coban, C., & Akira, S. (2008). Innate immune response to viral infection. *Cytokine*, 43(3), 336-341.
17. Redig, A. J., & Berliner, N. (2013). Pathogenesis and clinical implications of HIV-related anemia in 2013. *ASH Education Program Book*, 2013(1), 377-381.
18. Isanaka, S., Mugusi, F., Urassa, W., Willett, W. C., Bosch, R. J., Villamor, E., ... & Fawzi, W. W. (2011). Iron deficiency and anemia predict mortality in patients with tuberculosis. *The Journal of nutrition*, 142(2), 350-357.
19. Kendon, M., Knight, S. E., Ross, A., & Giddy, J. (2012). Timing of antiretroviral therapy initiation in adults with HIV-associated tuberculosis: Outcomes of therapy in an urban hospital in KwaZulu-Natal. *South African Medical Journal*, 102(12), 931-935.